title: Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis.
abstract: The use of drug delivery systems may reduce the toxicity and improve the activity of anti-leishmanial compounds. The activity of atovaquone (ATV)-loaded liposomes was compared by determination of median effective doses (ED(25) and ED(50)), with that of free ATV in a murine model of visceral leishmaniasis induced by Leishmania infantum. On day 0, mice were infected intravenously with 4.10(7) promastigotes and treated via the tail vein on days 15, 17 and 19 by free drug in a DMSO/cremophor/water solution (0.2 to 1.6 mg/kg body weight) or by liposomal drug (0.04 to 0.32 mg/kg body weight). Mice were killed and livers and spleens were removed and weighed on day 21 p.i. and liver parasite burdens evaluated using the Stauber method. Effective doses were determined using the Hill representation relating the percentage of parasite suppression to the dose. Liposomal ATV was significantly more effective than the free drug in reducing liver parasites (61.6% of parasite suppression at a dose of 0.32 mg/kg vs 34.9% at a dose of 1.6mg/kg). Liposomal ATV was 23 times more active than the free drug (ED(25) value=0. 02+/-0.01 mg/kg vs 0.46+/-0.15 mg/kg for free drug). It was not possible to obtain the ED(50) for free ATV because the dose-response curve reached a plateau around 33% of parasite suppression. Conversely, the ED(50) for liposomal ATV was 0.17+/-0.05 mg/kg. 100% efficacy of bound ATV could be obtained with a concentration of 1. 77+/-0.35 mg/kg. A significant decrease in spleen weights was also observed reflecting a leishmanicidal activity of ATV. These results suggest that liposome loaded ATV is more efficacious than the free drug against Leishmania infantum in this murine model.
authors.affiliation: Laboratoire de Pharmacotechnie, Service Pharmacie, C.H.U. H. Mondor, AP-HP, 94010, Créteil, France. alastier@micronet.fr
authors.forename: E
authors.initials: E
authors.lastname: Cauchetier
authors.forename: M
authors.initials: M
authors.lastname: Paul
authors.forename: D
authors.initials: D
authors.lastname: Rivollet
authors.forename: H
authors.initials: H
authors.lastname: Fessi
authors.forename: A
authors.initials: A
authors.lastname: Astier
authors.forename: M
authors.initials: M
authors.lastname: Deniau
mesh_terms: D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D053626:Atovaquone; D001835:Body Weight / Q000187:drug effects; D004339:Drug Compounding; D018314:Leishmania infantum; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008081:Liposomes; D008099:Liver / Q000187:drug effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use*; D013154:Spleen / Q000187:drug effects
chemical_list: D000981:Antiprotozoal Agents; D008081:Liposomes; D009285:Naphthoquinones; D053626:Atovaquone